Abliva AB (publ) (ABLI.ST)
SEK 0.44
(0.23%)
SEK 0.44
(0.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -57.24 Million SEK | 13.09% |
| 2022 | -65.85 Million SEK | -194.81% |
| 2021 | -22.33 Million SEK | 63.71% |
| 2020 | -61.55 Million SEK | -6.2% |
| 2019 | -57.95 Million SEK | -123.34% |
| 2018 | -25.95 Million SEK | 10.49% |
| 2017 | -28.99 Million SEK | 68.91% |
| 2016 | -93.25 Million SEK | 3.53% |
| 2015 | -96.66 Million SEK | -94.5% |
| 2014 | -49.69 Million SEK | -24.27% |
| 2013 | -39.99 Million SEK | -7.57% |
| 2012 | -37.17 Million SEK | -190.56% |
| 2011 | -12.79 Million SEK | 53.9% |
| 2010 | -27.75 Million SEK | -921.94% |
| 2009 | -2.71 Million SEK | 66.23% |
| 2008 | -8.04 Million SEK | -2470.12% |
| 2007 | -312.88 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -30.83 Million SEK | 46.13% |
| 2024 Q2 | -45.03 Million SEK | -46.06% |
| 2023 FY | -57.24 Million SEK | 13.09% |
| 2023 Q1 | -58.8 Million SEK | 10.71% |
| 2023 Q2 | -63.15 Million SEK | -7.39% |
| 2023 Q4 | -57.24 Million SEK | 1.51% |
| 2023 Q3 | -58.11 Million SEK | 7.98% |
| 2022 Q1 | 343 Thousand SEK | 101.54% |
| 2022 FY | -65.85 Million SEK | -194.81% |
| 2022 Q4 | -65.85 Million SEK | 10.33% |
| 2022 Q3 | -73.44 Million SEK | 45.66% |
| 2022 Q2 | -135.15 Million SEK | -39504.96% |
| 2021 Q3 | -63.26 Million SEK | 32.8% |
| 2021 Q4 | -22.33 Million SEK | 64.69% |
| 2021 FY | -22.33 Million SEK | 63.71% |
| 2021 Q1 | -47.97 Million SEK | 22.17% |
| 2021 Q2 | -94.14 Million SEK | -96.24% |
| 2020 Q4 | -61.64 Million SEK | 15.67% |
| 2020 Q3 | -73.09 Million SEK | -6.32% |
| 2020 Q1 | -29.12 Million SEK | 49.76% |
| 2020 FY | -61.64 Million SEK | -6.2% |
| 2020 Q2 | -68.74 Million SEK | -136.09% |
| 2019 FY | -57.95 Million SEK | -123.34% |
| 2019 Q2 | -99.07 Million SEK | 12.58% |
| 2019 Q1 | -113.33 Million SEK | -336.74% |
| 2019 Q3 | -79.77 Million SEK | 19.49% |
| 2019 Q4 | -57.95 Million SEK | 27.35% |
| 2018 Q3 | -38.37 Million SEK | 26.06% |
| 2018 Q4 | -25.95 Million SEK | 32.37% |
| 2018 Q1 | -15.75 Million SEK | 45.65% |
| 2018 FY | -25.95 Million SEK | 10.49% |
| 2018 Q2 | -51.89 Million SEK | -229.35% |
| 2017 Q4 | -28.99 Million SEK | 18.18% |
| 2017 Q2 | -46.98 Million SEK | 30.18% |
| 2017 FY | -28.99 Million SEK | 68.91% |
| 2017 Q1 | -67.28 Million SEK | 27.84% |
| 2017 Q3 | -35.43 Million SEK | 24.58% |
| 2016 Q2 | -132.28 Million SEK | -67.98% |
| 2016 FY | -93.25 Million SEK | 3.53% |
| 2016 Q1 | -78.74 Million SEK | 18.53% |
| 2016 Q4 | -93.25 Million SEK | 17.4% |
| 2016 Q3 | -112.88 Million SEK | 14.66% |
| 2015 Q4 | -96.66 Million SEK | 17.36% |
| 2015 FY | -96.66 Million SEK | -94.5% |
| 2015 Q3 | -116.96 Million SEK | 15.27% |
| 2015 Q2 | -138.04 Million SEK | -31.81% |
| 2015 Q1 | -104.73 Million SEK | -110.74% |
| 2014 Q1 | -97.09 Million SEK | -142.79% |
| 2014 Q2 | -74.51 Million SEK | 23.26% |
| 2014 FY | -49.69 Million SEK | -24.27% |
| 2014 Q4 | -49.69 Million SEK | 15.69% |
| 2014 Q3 | -58.94 Million SEK | 20.89% |
| 2013 Q4 | -39.99 Million SEK | -166.7% |
| 2013 Q2 | -22.97 Million SEK | 17.13% |
| 2013 Q1 | -27.71 Million SEK | 25.44% |
| 2013 Q3 | -14.99 Million SEK | 34.72% |
| 2013 FY | -39.99 Million SEK | -7.57% |
| 2012 Q1 | -9.96 Million SEK | 22.15% |
| 2012 Q2 | -49.42 Million SEK | -396.16% |
| 2012 Q3 | -43.56 Million SEK | 11.85% |
| 2012 Q4 | -37.17 Million SEK | 14.66% |
| 2012 FY | -37.17 Million SEK | -190.56% |
| 2011 Q4 | -12.79 Million SEK | 19.11% |
| 2011 FY | -12.79 Million SEK | 53.9% |
| 2011 Q1 | -23.8 Million SEK | 14.24% |
| 2011 Q3 | -15.81 Million SEK | 20.5% |
| 2011 Q2 | -19.89 Million SEK | 16.4% |
| 2010 Q4 | -27.75 Million SEK | 7.25% |
| 2010 Q3 | -29.92 Million SEK | 9.59% |
| 2010 FY | -27.75 Million SEK | -921.94% |
| 2010 Q2 | -33.09 Million SEK | -2605.61% |
| 2010 Q1 | 1.32 Million SEK | 148.64% |
| 2009 FY | -2.71 Million SEK | 66.23% |
| 2009 Q4 | -2.71 Million SEK | 0.0% |
| 2008 FY | -8.04 Million SEK | -2470.12% |
| 2007 FY | -312.88 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Isofol Medical AB (publ) | -138.14 Million SEK | 58.566% |
| Kancera AB (publ) | -45.69 Million SEK | -25.274% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -200.315% |
| Xintela AB (publ) | -7.8 Million SEK | -633.0% |
| AcouSort AB (publ) | -23.98 Million SEK | -138.639% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 30.268% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 207.547% |
| NextCell Pharma AB | -46.79 Million SEK | -22.332% |
| Amniotics AB (publ) | -5.63 Million SEK | -916.335% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -6101.517% |
| Simris Alg AB (publ) | 85.07 Million SEK | 167.282% |
| Active Biotech AB (publ) | -33.2 Million SEK | -72.41% |
| Alzinova AB (publ) | -21.22 Million SEK | -169.669% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2548.774% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -14.432% |
| BioArctic AB (publ) | -606.58 Million SEK | 90.564% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1160.0% |
| Camurus AB (publ) | -1.16 Billion SEK | 95.088% |
| Cantargia AB (publ) | -139.74 Million SEK | 59.04% |
| CombiGene AB (publ) | -101.44 Million SEK | 43.573% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -94.807% |
| Genovis AB (publ.) | -43.94 Million SEK | -30.266% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 31.646% |
| Mendus AB (publ) | -96.29 Million SEK | 40.557% |
| Intervacc AB (publ) | -88.16 Million SEK | 35.073% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 30.367% |
| LIDDS AB (publ) | -13.51 Million SEK | -323.623% |
| Lipum AB (publ) | -8.46 Million SEK | -576.196% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -79.284% |
| OncoZenge AB (publ) | -12.62 Million SEK | -353.314% |
| Saniona AB (publ) | 40.44 Million SEK | 241.519% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -26.59% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -332.68% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 82.843% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 134.466% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 55.798% |
| Ziccum AB (publ) | -2.13 Million SEK | -2578.521% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -14.631% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 379.083% |
| Corline Biomedical AB | -17.01 Million SEK | -236.468% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 31.648% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -45.346% |
| Aptahem AB (publ) | 2.9 Million SEK | 2067.929% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 82.605% |
| Fluicell AB (publ) | -2.76 Million SEK | -1971.661% |
| Biovica International AB (publ) | -58.73 Million SEK | 2.549% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 70.601% |
| 2cureX AB (publ) | -13.4 Million SEK | -327.069% |
| I-Tech AB | -83.26 Million SEK | 31.253% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 142.492% |
| Cyxone AB (publ) | -16.67 Million SEK | -243.371% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -2.423% |
| Biosergen AB | -1.88 Million SEK | -2939.83% |
| Nanologica AB (publ) | -9.38 Million SEK | -509.715% |
| SynAct Pharma AB | -61.75 Million SEK | 7.316% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -167.289% |
| BioInvent International AB (publ) | -236.3 Million SEK | 75.777% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 14.465% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1004.823% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -175.285% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1825.976% |